Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

CAR-T Digest - August 2020

Weekly Digest - June 2025

03 June 2025: Avenzo Therapeutics initiates Phase 1/2 clinical study of AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody drug conjugate

Avenzo Therapeutics has initiated a Phase 1/2 clinical trial for AVZO-1418, an EGFR/HER3 bispecific antibody-drug conjugate, in patients with advanced solid tumors
AVZO-1418 targets the EGFR-HER3 signaling pathway, which plays a critical role in driving tumor growth in cancers such as non-small cell lung, breast, and head and neck cancers
The trial is a first-in-human, open-label study designed to evaluate the safety, tolerability, and early clinical activity of AVZO-1418 both as a monotherapy and in combination regimens
This trial marks Avenzo’s second clinical program launched shortly after IND clearance, highlighting the company’s rapid advancement of its oncology pipeline